| The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition K Parmar, BS Kochupurakkal, JB Lazaro, ZC Wang, S Palakurthi, ... Clinical Cancer Research 25 (20), 6127-6140, 2019 | 115 | 2019 |
| Tumor innervation: Cancer has some nerve HD Reavis, HI Chen, R Drapkin Trends in cancer 6 (12), 1059-1067, 2020 | 55 | 2020 |
| MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity TB Branigan, D Kozono, AE Schade, P Deraska, HG Rivas, L Sambel, ... Cell reports 34 (9), 2021 | 26 | 2021 |
| NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair PV Deraska, C O’Leary, HD Reavis, S Labe, TK Dinh, JB Lazaro, ... Cell Death Discovery 4 (1), 10, 2018 | 17 | 2018 |
| The tubal epigenome–an emerging target for ovarian cancer HD Reavis, R Drapkin Pharmacology & therapeutics 210, 107524, 2020 | 15 | 2020 |
| Functional neuronal circuits promote disease progression in cancer AC Restaino, A Walz, SJ Vermeer, J Barr, A Kovács, RR Fettig, ... Science Advances 9 (19), eade4443, 2023 | 10 | 2023 |
| Quantitative, point-of-care immunoassay platform to guide and monitor sickle cell disease therapy X Yang, HD Reavis, CL Roberts, JS Kim Analytical chemistry 88 (16), 7904-7909, 2016 | 9 | 2016 |
| L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary K Doberstein, R Spivak, HD Reavis, J Hooda, Y Feng, PT Kroeger Jr, ... Communications biology 5 (1), 1362, 2022 | 8 | 2022 |
| H2Bub1: Guardian of chromatin accessibility in ovarian cancer H Reavis, R Drapkin Oncoscience 6 (7-8), 349, 2019 | 1 | 2019 |
| Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells HD Reavis, SM Gysler, GB McKenney, M Knarr, HJ Lusk, P Rawat, ... JCI insight, 2024 | | 2024 |
